论文部分内容阅读
将13 1I标记的抗CEA单抗静注至大肠癌疑诊患者体内 ,SPECT免疫显像后图像予以重建。结肠癌模型则随机分成化疗组和放免导向治疗 (RIT) 1、2、3组及对照组共五组 ,3周后测量肿瘤体积及重量 ,分析不同治疗对肿瘤生长的影响。结果 :4 9例放免导向诊断中 ,4 7例得到确诊 ,确诊率为 95 .9% ,假阳性、假阴性各有 1例 ,分期准确率为 86 .7%。除 5例患者出现一过性发热外 ,余均无不良反应。结肠癌模型通过不同治疗后肿瘤体积、重量变化显示 :RIT各组与化疗、对照组之间均有明显差异 ,其中肿瘤生长受抑制最明显的是瘤内注射RIT3组。认为13 1I C5 0放免显像是大肠癌诊断、分期和术后监测的有效、安全方法 ;188Re C5 0可有效抑制小鼠结肠癌模型的肿瘤生长 ,效果优于 5 Fu化疗 ,其中瘤内注射给药的疗效最优
The 131I-labeled anti-CEA monoclonal antibody was injected intravenously into suspected colorectal cancer patients, and the images were reconstructed after SPECT immunohistochemistry. Colon cancer models were randomly divided into chemotherapy group and RIT group 1, 2 and 3 groups and control group. Five weeks later, tumor volume and weight were measured, and the effects of different treatments on tumor growth were analyzed. Results: In 49 cases of radioimmunoassay, 47 cases were diagnosed with a diagnosis rate of 95.9%. There were 1 case with false positives and false negatives, and the accuracy rate was 86.7%. Except 5 cases of transient fever, there was no adverse reaction. The colon cancer model showed changes in tumor volume and weight after different treatments: There were significant differences between RIT groups and chemotherapy and control groups, and the most significant inhibition of tumor growth was intratumoral injection of RIT3. It is considered that 13 1I C5 0 radioimmunoassay is an effective and safe method for the diagnosis, staging, and postoperative monitoring of colorectal cancer. 188Re C50 can effectively inhibit tumor growth in mouse colon cancer models, and the effect is better than 5 Fu chemotherapy, including intratumoral injection. Optimal therapeutic effect